Last reviewed · How we verify

Subanesthetic dose of esketamine

bo xu · Phase 1 active Small molecule

Subanesthetic dose of esketamine is a Small molecule drug developed by bo xu. It is currently in Phase 1 development. Also known as: Esketamine hydrochloride injection.

At a glance

Generic nameSubanesthetic dose of esketamine
Also known asEsketamine hydrochloride injection
Sponsorbo xu
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Subanesthetic dose of esketamine

What is Subanesthetic dose of esketamine?

Subanesthetic dose of esketamine is a Small molecule drug developed by bo xu.

Who makes Subanesthetic dose of esketamine?

Subanesthetic dose of esketamine is developed by bo xu (see full bo xu pipeline at /company/bo-xu).

Is Subanesthetic dose of esketamine also known as anything else?

Subanesthetic dose of esketamine is also known as Esketamine hydrochloride injection.

What development phase is Subanesthetic dose of esketamine in?

Subanesthetic dose of esketamine is in Phase 1.

Related